Bayer

Soil Amendments Market Projected to Reach $33.47 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Tuesday, March 26, 2024
Soil, Health, Climate change, Farmer, Drainage, Growth, Manure, Potassium, Agriculture, Nitrogen, Intelligence, Common, Research, Inorganic compound, Bayer, UPL, Food security, Fertility, Water purification, CAP, Carbon, Mineral, Biodiversity, Yara International, Phosphorus, Table

Soil amendments have gained importance for their pivotal role in mitigating climate change by maintaining soil health.

Key Points: 
  • Soil amendments have gained importance for their pivotal role in mitigating climate change by maintaining soil health.
  • Innovations and advancements are anticipated to refine soil amendments' effectiveness and environmental compatibility, promising tailor-made solutions based on specific soil conditions and crop necessities.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Soil Amendments Market.
  • "Dive into the Soil Amendments Market Landscape: Explore 193 Pages of Insights, 928 Tables, and 28 Figures"

Soil Amendments Market Projected to Reach $33.47 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Tuesday, March 26, 2024
Soil, Health, Climate change, Farmer, Drainage, Growth, Manure, Potassium, Agriculture, Nitrogen, Intelligence, Common, Research, Inorganic compound, Bayer, UPL, Food security, Fertility, Water purification, CAP, Carbon, Mineral, Biodiversity, Yara International, Phosphorus, Table

Soil amendments have gained importance for their pivotal role in mitigating climate change by maintaining soil health.

Key Points: 
  • Soil amendments have gained importance for their pivotal role in mitigating climate change by maintaining soil health.
  • Innovations and advancements are anticipated to refine soil amendments' effectiveness and environmental compatibility, promising tailor-made solutions based on specific soil conditions and crop necessities.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Soil Amendments Market.
  • "Dive into the Soil Amendments Market Landscape: Explore 193 Pages of Insights, 928 Tables, and 28 Figures"

Radiopharmaceuticals Market to Reach $11.6 Billion by 2034 as Cancer Treatment Gains Traction - Future Market Insights, Inc.

Retrieved on: 
Monday, March 25, 2024
Curium, FMI, Novartis, Eli Lilly, Face, FAP, Associate, Hospital, Bayer, Cancer, Actinium-225, Medicare, Radiopharmaceutical, Radio, Therapy, Eli Lilly and Company, Government

NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide. With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade. Rising incidences of cancer and cancer-associated diseases are one of the main reasons for that.

Key Points: 
  • This report by FMI dives deep into why this market is thriving, what bumps it might face, and the exciting possibilities ahead.
  • NEWARK, Del., March 25, 2024 /PRNewswire/ -- Radiopharmaceuticals is one of the most effective and newly emerged cancer treatment methodologies, which is gaining popularity in the medicare sector worldwide.
  • With the current valuation of US$ 6,972.1 million, the Radiopharmaceuticals market is very likely to have a promising future in the coming decade.
  • Although the market is still in its nascent stages, it is slated to pick up some pace in the coming decade.

Bayer AG and Lavie Bio Continue for Second Year of Biofungicides Validation Following Successful Lab and Greenhouse Testing

Retrieved on: 
Tuesday, March 19, 2024
AG, Farmer, Vegetable, Partnership, Bayer, BDD, Oomycete

The tests have demonstrated the efficacy of Lavie Bio's biofungicides in addressing devastating diseases that affect fruits and vegetables worldwide.

Key Points: 
  • The tests have demonstrated the efficacy of Lavie Bio's biofungicides in addressing devastating diseases that affect fruits and vegetables worldwide.
  • Building on these positive outcomes, the companies are progressing to a second year of validation trials in field experiments.
  • "Biofungicides are a real opportunity for innovation, and we are looking forward to the new solutions this partnership with Lavie Bio helps us deliver together."
  • Lavie Bio's commitment to refining its promising bio fungicides through joint validation trials with Bayer AG serves as a powerful testament to the company's development capabilities, leveraging its innovative BDD platform powered by Evogene's MicroBoost AI tech-engine.

CRISPR Technology Takes Center Stage at SXSW 2024 for the First Time

Retrieved on: 
Friday, March 8, 2024
Breeding, CRISPR, Doctor of Philosophy, Biotechnology, Gene editing, Research, Plant, Food, Entrepreneurship, Conference, Health, Climate change, Vegetable, Bayer, Medicine, Agriculture, Taste, Bill, Wageningen University & Research, Partnership

Durham, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- The panel “The First CRISPR Foods Have Arrived” at this year’s SXSW Conference included leading agricultural scientists, researchers, and innovation drivers.

Key Points: 
  • Durham, N.C., March 08, 2024 (GLOBE NEWSWIRE) -- The panel “The First CRISPR Foods Have Arrived” at this year’s SXSW Conference included leading agricultural scientists, researchers, and innovation drivers.
  • “We have steadily seen an increase in consumer interest around using technology for produce innovation.
  • “With effective application of the technology, we can use CRISPR to deliver major societal and climate benefits through improvements in the food and agriculture sector.
  • This is an incredibly exciting time.”
    As CRISPR technology has advanced, it has attracted a new generation of researchers across the world.

EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

Retrieved on: 
Friday, March 8, 2024
FACS, Regeneron Pharmaceuticals, Research, HD, Food, Floater, Cataract, Consultant, Aflibercept, Diabetic retinopathy, European, Intraocular pressure, Safety, DR, Society, Retinal, Bayer, Diabetes, Patient, Publication, Pharmaceutical industry

TARRYTOWN, N.Y., March 08, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced The Lancet published one-year results from the pivotal PULSAR and PHOTON trials for EYLEA® HD (aflibercept) Injection 8 mg. Specifically, the publications detailed data demonstrating that EYLEA HD extended dosing regimens were non-inferior to EYLEA® (aflibercept) Injection 2 mg for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

Key Points: 
  • Specifically, the publications detailed data demonstrating that EYLEA HD extended dosing regimens were non-inferior to EYLEA® (aflibercept) Injection 2 mg for both the treatment of wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
  • “Less than a year after its approval, EYLEA HD has already made an impact in the treatment of wet age-related macular degeneration and diabetic macular edema.
  • EYLEA HD has provided disease control for my tough-to-treat cases of diabetic eye disease and allowed both my diabetic and wet age-related macular degeneration patients to enjoy less frequent dosing with a similar safety profile to EYLEA.”
    PULSAR and PHOTON are two double-masked, active-controlled pivotal trials evaluating EYLEA HD compared to EYLEA.
  • In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.

Pairwise Named one of America’s Top GreenTech Companies 2024

Retrieved on: 
Thursday, March 7, 2024
CRISPR, Gene editing, Weather, Greentech, Cherry, Overalls, Statista, TIME, Food, Entrepreneurship, Climate change, Bayer, Agriculture, Water, Partnership

Durham, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Pairwise, a technology company pioneering the application of CRISPR in food and agriculture, has earned acknowledged from TIME magazine as one of America’s Top Greentech Companies .

Key Points: 
  • Durham, N.C., March 07, 2024 (GLOBE NEWSWIRE) -- Pairwise, a technology company pioneering the application of CRISPR in food and agriculture, has earned acknowledged from TIME magazine as one of America’s Top Greentech Companies .
  • This list, developed by TIME in partnership with Statista, recognizes 250 of the top sustainability-focused companies that are driving positive impact within the GreenTech industry.
  • Companies were evaluated based on their impact, financial strength, and innovation; the 250 companies with highest scores were named to the list.
  • Pairwise was ranked 56th overall and 8th among AgTech companies.

Zenas BioPharma Appoints Patricia Allen to its Board of Directors

Retrieved on: 
Wednesday, March 6, 2024
Acquisition, Inflammation, Bryant University, Alkermes, Chairperson, Audit committee, Business administration, Therapy, Bayer, Patient, LLP, Auditor, Management

Ms. Allen joins the Zenas Board of Directors with over 20 years of experience leading finance, investor relations, business development, human resources, operations and IT at global public and private biotechnology companies.

Key Points: 
  • Ms. Allen joins the Zenas Board of Directors with over 20 years of experience leading finance, investor relations, business development, human resources, operations and IT at global public and private biotechnology companies.
  • “We are pleased to welcome Patty to our Board of Directors,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma.
  • “She has successfully led cross-organizational functions and served on the board of directors of both private and public global biotechnology companies.
  • Prior to Vividion, Ms. Allen was the Chief Financial Officer at Zafgen, Inc. (now Larimer Therapeutics).

BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months

Retrieved on: 
Wednesday, March 6, 2024
Senior, MD, Neurology, Executive Committee, Conference, Safety, University, MDS, Therapy, Bayer, Patient, Disease, Brain, Pharmaceutical industry

In addition, exploratory clinical endpoints improved compared to baseline assessments in both cohorts, with participants in the high dose cohort showing greater improvement than those in the low dose cohort.

Key Points: 
  • In addition, exploratory clinical endpoints improved compared to baseline assessments in both cohorts, with participants in the high dose cohort showing greater improvement than those in the low dose cohort.
  • Time spent in the “OFF” state showed a mean decrease of 2.7 hours after 18 months.
  • “We are excited to see the continued positive trends in the data from bemdaneprocel’s phase I trial at 18 months,” said Ahmed Enayetallah, Senior Vice President and Head of Development at BlueRock Therapeutics.
  • “There are good reasons to be optimistic about these early data, and we are excited to move to phase II later this year.”

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

Retrieved on: 
Wednesday, March 6, 2024
Biotechnology Innovation Organization, Merck, Drug development, BIO, Sale, PAH, Merck & Co., Chairperson, Therapy, Bayer, Patient, Pharmaceutical industry

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board.

Key Points: 
  • WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board.
  • Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board.
  • “We are pleased to have Habib take on the role of Chair of the Board,” said Tim Noyes, Chief Executive Officer of Aerovate Therapeutics.
  • I would also like to thank Mark for his significant contributions and commitment to Aerovate, and I look forward to continuing to work together.”
    “I am honored to assume the role of Board Chair for Aerovate during this exciting time for the company,” said Mr. Dable.